Australia's largest stock trading and investment forum Australia's #1 stock forum

NUH

0.00%

8.1¢ nuheara limited

Roweka has been around a lot lot longer than you and has never...

First 66 Last

Share
Profile

Follow
Bb1974

289 Posts.

157

08/07/24

19:19

Post #: 74660689
Share

Originally posted by the trickster: ↑

I am sorry but your argument is false.

You cannot suggest that based on the 4D balance date 31st Dec 2023 they are trading insolvent when they had more cash on hand as a result of the capital raise in November as well as the R&D tax rebate than the prior half yr.

If you are going to argue that they are insolvent as at 31st Dec 2023, then they are insolvent as at 30th June 2023.

Not lodging the 4D doesnt give you any protection from trading while insolvent rules and the penalties are severe including potential jail time.

I told you the reason why they are in a trading halt, they are using the 4D as a mechanism to trigger an extended trading halt while they engage in negotiations. You don’t seem to be paying attention.
Its a very unethical and corrupt mechanism to use but technically not illegal. They can hold it back based on directors not signing off or argument over some technicality. The fact that they have lodged the latest 4C and the fact that accounts can be reconstructed forensically, they have no where to hide if they are deliberately trading while insolvent, and that does not mean just trading on the exchange, it means trading in “business”. Not lodging a 4D is no protection from the law. Your argument that they havent lodged the prior 4D because of insolvent trading is nonsensical.

Unfortunately the CEOof NUH and the Board are not morally upstanding corporate citizens but behave as shysters.

As soon as the 4D is lodged, they have limited levers available to stop the ASX re-instating them for trade. Miller’s behaviour is unconscionable. And to think this quack believes he is entitled to performance shares. It will be interesting how this works with respect to insider trading rules. Allocating yourself shares while negotiating deals is no different to buying on market based on insider information. We shall see what will happen in time but certainly it may present as a serious problem depending on how events transpire.

My monthly cash burn estimate is reasonable , typically they average around $1.8mln plus per qtr sometimes allot more, but they have cut that way down , cutting salary expenses, marketing expenses etc. We dont know the exact details are as the accounts have not been released for the last qtr but $500k/month seems to be a reasonable estimate to work with. It may be a little higher or lower, but it is certainly not way off the way you are suggesting.

Expand

Roweka has been around a lot lot longer than you and has never been wrong on the accountancy side of things - ever.

NUH Price at posting: 8.1¢ Sentiment: None Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

GNP

Genus scores major works contract with Western Power, to earn $50M in first year

EM2

Eagle Mountain unlocks porphyry Cu targets at Arizona play

TLS

Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago

STX

Strike Energy wins EPA green tick for West Erregulla; AGIG also awarded pipeline licence

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

There are more pages in this discussion • 8 more messages in this thread...

First 66 Last

Add NUH (ASX) to my watchlist

(20min delay)
Last 8.1¢		Change 0.000(0.00%)		Mkt cap ! $21.75M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Roweka has been around a lot lot longer than you and has never...

Genus scores major works contract with Western Power, to earn $50M in first year

Eagle Mountain unlocks porphyry Cu targets at Arizona play

Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago

Strike Energy wins EPA green tick for West Erregulla; AGIG also awarded pipeline licence

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Featured News

Roweka has been around a lot lot longer than you and has never...

Top Stories

Genus scores major works contract with Western Power, to earn $50M in first year

Eagle Mountain unlocks porphyry Cu targets at Arizona play

Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago

Strike Energy wins EPA green tick for West Erregulla; AGIG also awarded pipeline licence

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Featured News